SEARCH

SEARCH BY CITATION

References

  • Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR et al. (2005). The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127131.
  • Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD et al. (2005). The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92: 798806.
  • Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC et al. (2007). Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92: 29772983.
  • Asarian L, Eckel LA, Geary N (1998). Behaviorally specific inhibition of sham feeding by amylin. Peptides 19: 17111718.
  • Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ (2010). Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab 95: 23672375.
  • Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ (2010). Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151: 46784687.
  • Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004). A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 24922500.
  • Baggio LL, Huang Q, Cao X, Drucker DJ (2008). An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134: 11371147.
  • Baldo BA, Kelley AE (2001). Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior. Am J Physiol Regul Integr Comp Physiol 281: R1232R1242.
  • Balkan B, Li X (2000). Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449R1454.
  • Banks WA, Kastin AJ (1998). Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19: 883889.
  • Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB (1995). Permeability of the blood-brain barrier to amylin. Life Sci 57: 19932001.
  • Baraboi ED, Smith P, Ferguson AV, Richard D (2010). Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist. Am J Physiol Regul Integr Comp Physiol 298: R1098R1110.
  • Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ (2009). Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 58: 28202827.
  • Barth SW, Riediger T, Lutz TA, Rechkemmer G (2004). Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor-activity modifying proteins in the rat. Brain Res 997: 97102.
  • Beaumont K, Kenney MA, Young AA, Rink TJ (1993). High affinity amylin binding sites in rat brain. Mol Pharmacol 44: 493497.
  • Becskei C, Grabler V, Edwards GL, Riediger T, Lutz TA (2007). Lesion of the lateral parabrachial nucleus attenuates the anorectic effect of peripheral amylin and CCK. Brain Res 1162: 7684.
  • Becskei C, Lutz TA, Riediger T (2009). Diet-derived nutrients mediate the inhibition of hypothalamic NPY neurons in the arcuate nucleus of mice during refeeding. Am J Physiol Regul Integr Comp Physiol 297: R100R110.
  • Bello NT, Kemm MH, Ofeldt EM, Moran TH (2010). Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol 299: R945R952.
  • Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J et al. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86: 326338.
  • Bhavsar S, Watkins J, Young A (1998). Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 64: 557561.
  • Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ et al. (2010). Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151: 14731486.
  • Bojanowska E, Nowak A (2007). Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 58: 349360.
  • Brennan IM, Feltrin KL, Horowitz M, Smout AJ, Meyer JH, Wishart J et al. (2005). Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 288: R1477R1485.
  • Bullock BP, Heller RS, Habener JF (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 29682978.
  • Campos RV, Lee YC, Drucker DJ (1994). Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134: 21562164.
  • Cegla J, Tan TM, Bloom SR (2010). Gut-brain cross-talk in appetite regulation. Curr Opin Clin Nutr Metab Care 13: 588593.
  • Chance WT, Balasubramaniam A, Chen X, Fischer JE (1992). Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin. Peptides 13: 961964.
  • Chen Q, Pinon DI, Miller LJ, Dong M (2010). Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity. J Biol Chem 285: 2450824518.
  • Christensen M, Knop FK (2010). Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 10: 124132.
  • Christopoulos A, Kenakin T (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323374.
  • Colburn WA, Gottlieb AB, Koda J, Kolterman OG (1996). Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 36: 1324.
  • Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, Moore AJ et al. (2008). Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 23: 11821193.
  • Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749757.
  • De A, DiMarchi RD (2010). Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. Biopolymers 94: 448456.
  • Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK et al. (2010). Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95: 215221.
  • Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU et al. (1993). Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 19071910.
  • Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J (1997). Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46: 792800.
  • Doyle ME, Egan JM (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546593.
  • Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J (1994). Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135: 20702075.
  • Field BC, Chaudhri OB, Bloom SR (2009). Obesity treatment: novel peripheral targets. Br J Clin Pharmacol 68: 830843.
  • Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA et al. (1999). Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 48: 19791986.
  • Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P et al. (1998). Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250: 271277.
  • Gedulin BR, Rink TJ, Young AA (1997). Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 6770.
  • Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD (1993). Cloning and functional expression of a human glucagon-like peptide-1 receptor. Biochem Biophys Res Commun 196: 141146.
  • Green BD, Gault VA, O'Harte FP, Flatt PR (2004). Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 10: 36513662.
  • Gromada J, Rorsman P (2004). New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Horm Metab Res 36: 822829.
  • Gromada J, Brock B, Schmitz O, Rorsman P (2004). Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 95: 252262.
  • Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C (2004). Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 287: R562R567.
  • Hamilton A, Patterson S, Porter D, Gault VA, Holscher C (2011). Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89: 481489.
  • Hansotia T, Drucker DJ (2005). GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 128: 125134.
  • Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K et al. (2004). Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53: 13261335.
  • Harkavyi A, Whitton PS (2010). Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159: 495501.
  • Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5: 519.
  • Hayashi Y, Yamamoto M, Mizoguchi H, Watanabe C, Ito R, Yamamoto S et al. (2009). Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells. Mol Endocrinol 23: 19901999.
  • de Heer J, Rasmussen C, Coy DH, Holst JJ (2008). Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51: 22632270.
  • Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG et al. (2004). Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12: 661668.
  • Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA (2009). Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 587: 47494759.
  • Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87: 14091439.
  • Holst JJ, Burcelin R, Nathanson E (2011). Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27: 547558.
  • Irwin N, Flatt PR, Patterson S, Green BD (2010). Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol 628: 268273.
  • Kastin AJ, Akerstrom V, Pan W (2002). Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18: 714.
  • Kinzig KP, D'Alessio DA, Seeley RJ (2002). The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22: 1047010476.
  • Klopfenstein BK, Krisky C, Rooney W, Purnell JQ (2010). Amygdala activation by leptin predicts food intake in lean men. In: Late Breaking Abstraction – The Obesity Society.
  • Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG (1992). Amylin concentrations and glucose control. Lancet 339: 11791180.
  • Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL et al. (2010). Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456465.
  • Korner M, Stockli M, Waser B, Reubi JC (2007). GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48: 736743.
  • Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C (1997). Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257270.
  • Li N, Fang CY, Wang ZZ, Wang YL, Wang FB, Gao E et al. (2004). Expression of calcitonin gene-related peptide type 1 receptor mRNA and their activity-modifying proteins in the rat nucleus accumbens. Neurosci Lett 362: 146149.
  • Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al. (2009). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106: 12851290.
  • Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW et al. (2010). GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 12051219.
  • Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG et al. (2001). Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438: 382387.
  • Lund PK, Goodman RH, Dee PC, Habener JF (1982). Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 79: 345349.
  • Lutz TA, Del Prete E, Scharrer E (1994). Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 55: 891895.
  • Lutz TA, Del Prete E, Scharrer E (1995). Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16: 457462.
  • Lutz TA, Althaus J, Rossi R, Scharrer E (1998a). Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am J Physiol 274 (Part 2): R1777R1782.
  • Lutz TA, Senn M, Althaus J, Del Prete E, Ehrensperger F, Scharrer E (1998b). Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19: 309317.
  • Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S et al. (2007). Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 293: R1855R1863.
  • Mack C, Wilson J, Gu G, Cole R, Roland R, Vu C et al. (2008). Central activation and weight-lowering actions of AC164209, a peptide hybrid linking a glucagon-like peptide-1 (GLP-1) receptor agonist and an amylin mimetic. The Obesity Society, P-489.
  • Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL et al. (2010). Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond) 34: 385395.
  • McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N et al. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 333339.
  • Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS, Holst JJ (2011). An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13: 394407.
  • Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM (2009). Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 18: 359367.
  • Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG et al. (2009). Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem 52: 77887799.
  • Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C et al. (2010). Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther 88: 243250.
  • Mentlein R, Gallwitz B, Schmidt WE (1993). Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829835.
  • Merchenthaler I, Lane M, Shughrue P (1999). Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261280.
  • Mollet A, Gilg S, Riediger T, Lutz TA (2004). Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol Behav 81: 149155.
  • Morley JE, Suarez MD, Mattamal M, Flood JF (1997). Amylin and food intake in mice: effects on motivation to eat and mechanism of action. Pharmacol Biochem Behav 56: 123129.
  • Mortensen K, Christensen LL, Holst JJ, Orskov C (2003). GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114: 189196.
  • Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006). Central nervous system control of food intake and body weight. Nature 443: 289295.
  • Mulder H, Gebre-Medhin S, Betsholtz C, Sundler F, Ahren B (2000). Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. Am J Physiol Endocrinol Metab 278: E684E691.
  • Murage EN, Schroeder JC, Beinborn M, Ahn JM (2008). Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg Med Chem 16: 1010610112.
  • Murage EN, Gao G, Bisello A, Ahn JM (2010). Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem 53: 64126420.
  • Nagell CF, Wettergren A, Orskov C, Holst JJ (2006). Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667672.
  • Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A (1996). Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271 (Part 1): E808E813.
  • Nathan Y, Lee A, Evans T, Coates S, Reed LJ, Brammer MJ et al. (2010). Acute administration of the GLP-1 receptor agonist exenatide restores impaired central responses to food ingestion in type 2 diabetes. In: European Association For The Study of Diabetes.
  • Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87: 12391246.
  • Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM et al. (2005). Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146: 51205127.
  • Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J (2011). Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 96: 229236.
  • Nielsen LL, Young AA, Parkes DG (2004). Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117: 7788.
  • Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL (1990). Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85: 973976.
  • Orskov C, Poulsen SS, Moller M, Holst JJ (1996). Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832835.
  • Osto M, Wielinga PY, Alder B, Walser N, Lutz TA (2007). Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin. Physiol Behav 91: 566572.
  • Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA et al. (2007). Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 35: 511517.
  • Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303310.
  • Perry T, Greig NH (2005). Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2: 377385.
  • Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 22582266.
  • Potes CS, Lutz TA (2010). Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 100: 511518.
  • Potes CS, Turek VF, Cole RL, Vu C, Roland BL, Roth JD et al. (2010). Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. Am J Physiol Regul Integr Comp Physiol 299: R623R631.
  • Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W et al. (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54: 233246.
  • Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H et al. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 17: 17361743.
  • Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM (2011). Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 19: 121127.
  • Riediger T, Schmid HA, Lutz T, Simon E (2001). Amylin potently activates AP neurons possibly via formation of the excitatory second messenger cGMP. Am J Physiol Regul Integr Comp Physiol 281: R1833R1843.
  • Riediger T, Zuend D, Becskei C, Lutz TA (2004). The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis. Am J Physiol Regul Integr Comp Physiol 286: R114R122.
  • Rocca AS, Brubaker PL (1999). Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 16871694.
  • Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM (2006). Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147: 58555864.
  • Roth JD, Coffey T, Jodka CM, Maier H, Athanacio JR, Mack CM et al. (2007). Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148: 60546061.
  • Roth JD, Mack CM, Soares CJ, Ghosh SS, Parkes DG (2008a). Amylin-Based Pharmacotherapy: past, present and future. Immun Endoc & Metab Agents Med Chem 8: 317324.
  • Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE et al. (2008b). Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105: 72577262.
  • Roth JD, Maier H, Chen S, Roland BL (2009). Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 66: 306310.
  • Roth JD, Trevaskis JL, Turek VF, Parkes DG (2010). ‘Weighing in’ on synergy: preclinical research on neurohormonal anti-obesity combinations. Brain Res 1350: 8694.
  • Rowland NE, Richmond RM (1999). Area postrema and the anorectic actions of dexfenfluramine and amylin. Brain Res 820: 8691.
  • Rowland NE, Crews EC, Gentry RM (1997). Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 71: 171174.
  • Rushing PA, Seeley RJ, Air EL, Lutz TA, Woods SC (2002). Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences. Peptides 23: 985988.
  • Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W (2009). Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 11741181.
  • Salehi M, Vahl TP, D'Alessio DA (2008). Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 93: 49094916.
  • Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S et al. (1999). Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48: 10451053.
  • Scrocchi LA, Drucker DJ (1998). Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinology 139: 31273132.
  • Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL et al. (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 12541258.
  • Scrocchi LA, Brown TJ, Drucker DJ (1997). Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. Diabetes 46: 20292034.
  • Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC et al. (2000). The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20: 16161621.
  • Seo S, Ju S, Chung H, Lee D, Park S (2008). Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 55: 867874.
  • Seth R, Knight WD, Overton JM (2010). Combined amylin-leptin treatment lowers blood pressure and adiposity in lean and obese rats. Int J Obes (Lond) DOI: 10.1038/ijo.2010.262.
  • Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2009). Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 14: 413419.
  • Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W et al. (2008). Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106: 455463.
  • Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR et al. (1999). Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 79: 93102.
  • Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA et al. (2001). Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 280: E443E449.
  • Skibicka KP, Alhadeff AL, Grill HJ (2009). Hindbrain cocaine- and amphetamine-regulated transcript induces hypothermia mediated by GLP-1 receptors. J Neurosci 29: 69736981.
  • Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD et al. (2010). Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59: 30993107.
  • Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC et al. (2007). Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 293: E620E627.
  • Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C (2010). Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 92: 810817.
  • Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL (2005). Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 37483756.
  • Tang-Christensen M, Cowley MA (2007). GLP-1 analogs: satiety without malaise? Am J Physiol Regul Integr Comp Physiol 293: R981R982.
  • Tang-Christensen M, Vrang N, Larsen PJ (1998). Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47: 530537.
  • Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T et al. (2007). Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17: 54725478.
  • Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC et al. (1997). Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 272 (Part 2): R726R730.
  • Thorens B (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 86418645.
  • Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 16781682.
  • Tomas E, Stanojevic V, Habener JF (2011). GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 169: 4348.
  • Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B et al. (2008). Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149: 56795687.
  • Trevaskis JL, Parkes DG, Roth JD (2010a). Insights into amylin-leptin synergy. Trends Endocrinol Metab 21: 473479.
  • Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, Roth JD (2010b). Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin? Physiol Behav 100: 187195.
  • Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, Reynolds JM et al. (2010c). Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 151: 56575668.
  • Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G et al. (2010). Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 151: 143152.
  • Turner AG, Tjahyono F, Chiu WS, Skinner J, Sawyer R, Moore AJ et al. (2011). The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone 48: 354361.
  • Unger RH, Orci L (2010). Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 107: 1600916012.
  • Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD et al. (2007). Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 49654973.
  • Vine W, Smith P, LaChappell R, Blase E, Lumpkin R, Young A (1998). Nephrectomy decreases amylin and pramlintide clearance in rats. Horm Metab Res 30: 514517.
  • Wan S, Coleman FH, Travagli RA (2007). Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest Liver Physiol 292: G1474G1482.
  • Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ (1997). The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597601.
  • Weyer C, Maggs DG, Young AA, Kolterman OG (2001). Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7: 13531373.
  • Wickbom J, Herrington MK, Permert J, Jansson A, Arnelo U (2008). Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy. Regul Pept 148: 2125.
  • Williams DL (2009). Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 150: 29973001.
  • Williams DL, Baskin DG, Schwartz MW (2006). Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55: 33873393.
  • Williams DL, Baskin DG, Schwartz MW (2009). Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150: 16801687.
  • Witte AB, Gryback P, Jacobsson H, Naslund E, Hellstrom PM, Holst JJ et al. (2011). Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. Scand J Gastroenterol 46: 428435.
  • World Health Organization (2011) http://www.who.int/diabetes/facts/world_figures/en/index.html . Prevalence of Diabetes Worldwide. In: World Health Organization.
  • Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL et al. (2001). Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40: 28602869.
  • Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN et al. (2003). Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23: 29392946.
  • Young A (2005a). Clinical studies. Adv Pharmacol 52: 289320.
  • Young A (2005b). Historical background. Adv Pharmacol 52: 118.
  • Young A (2005c). Inhibition of gastric emptying. Adv Pharmacol 52: 99121.
  • Young A (2005d). Inhibition of insulin secretion. Adv Pharmacol 52: 173192.
  • Zhang Z, Liu X, Morgan DA, Kuburas A, Thedens DR, Russo AF et al. (2011). Neuronal Receptor Activity Modifying Protein-1 Promotes Energy Expenditure in Mice. Diabetes 60: 10631071.